Nanjing Vishee Medical Technology Co., Ltd (688580.SS)
CNY 31.76
(-4.31%)
CNY 31.76
(-4.31%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 171.46 Million CNY | 40.83% |
| 2022 | 125 Million CNY | -40.82% |
| 2021 | 209.07 Million CNY | 19.05% |
| 2020 | 175.54 Million CNY | 42.23% |
| 2019 | 123.8 Million CNY | 58.94% |
| 2018 | 78.03 Million CNY | 65.91% |
| 2017 | 47.8 Million CNY | 145.96% |
| 2016 | 18.96 Million CNY | -22.71% |
| 2015 | 24.68 Million CNY | 117.03% |
| 2014 | 13.68 Million CNY | 45.59% |
| 2013 | 7.39 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 31.84 Million CNY | -12.95% |
| 2024 Q1 | 23.05 Million CNY | -33.28% |
| 2024 Q2 | 25.5 Million CNY | 25.77% |
| 2023 Q3 | 35.27 Million CNY | -21.7% |
| 2023 FY | - CNY | 40.83% |
| 2023 Q4 | 41.03 Million CNY | 16.33% |
| 2023 Q2 | 45.05 Million CNY | 36.01% |
| 2023 Q1 | 33.12 Million CNY | -15.76% |
| 2022 Q2 | 22.94 Million CNY | 28.96% |
| 2022 Q1 | 17.78 Million CNY | -76.5% |
| 2022 Q4 | 39.32 Million CNY | 46.7% |
| 2022 FY | - CNY | -40.82% |
| 2022 Q3 | 26.8 Million CNY | 16.84% |
| 2021 FY | - CNY | 19.05% |
| 2021 Q1 | 35.62 Million CNY | -47.06% |
| 2021 Q2 | 43.45 Million CNY | 22.0% |
| 2021 Q3 | 43.68 Million CNY | 0.53% |
| 2021 Q4 | 75.69 Million CNY | 73.26% |
| 2020 Q3 | 37.31 Million CNY | -17.24% |
| 2020 Q1 | 21.78 Million CNY | -37.65% |
| 2020 Q4 | 67.28 Million CNY | 80.31% |
| 2020 Q2 | 45.08 Million CNY | 107.0% |
| 2020 FY | - CNY | 42.23% |
| 2019 Q3 | 31.66 Million CNY | 1.43% |
| 2019 Q4 | 34.93 Million CNY | 10.31% |
| 2019 Q2 | 31.22 Million CNY | 42.94% |
| 2019 Q1 | 21.84 Million CNY | 0.0% |
| 2019 FY | - CNY | 58.94% |
| 2018 FY | - CNY | 65.91% |
| 2017 FY | - CNY | 145.96% |
| 2016 Q1 | 5.49 Million CNY | 0.0% |
| 2016 FY | - CNY | -22.71% |
| 2016 Q2 | 5.49 Million CNY | 0.0% |
| 2015 Q1 | 4.37 Million CNY | 0.0% |
| 2015 FY | - CNY | 117.03% |
| 2015 Q2 | 4.37 Million CNY | 0.0% |
| 2014 FY | - CNY | 45.59% |
| 2013 FY | - CNY | 0.0% |